G1 Therapeutics Appoints Chief Business Officer

G1 Therapeutics, Inc. has appointed Mark Avagliano as Chief Business Officer. In this role, Mr. Avagliano will serve as a member of the G1 executive team, responsible for leading the company’s global partnering and corporate development strategy and execution.
 
Prior to joining G1, Mr. Avagliano was Vice President, Corporate Development at Pfizer Inc., where he was responsible for the evaluation, planning and execution of significant corporate level transactions and oversaw the Mergers and Acquisitions, Transactions and Valuations, and Out-licensing groups. During his fifteen years at Pfizer, Mr. Avagliano successfully led the execution of numerous transactions, including acquisitions, divestitures, joint ventures, co-developments, co-promotions, product licenses, research collaborations, and public market separations. 
 
"Mark has experience executing a broad range of corporate development deals, including partnerships, joint ventures and strategic transactions. We are excited for him to lead our corporate development function, with the goal of bringing our investigational therapies to patients around the world while creating value for our shareholders," said Mark Velleca, M.D., Ph.D., Chief Executive Officer. "We are approaching important clinical, regulatory and commercial milestones across our pipeline, so this is an ideal time to add Mark’s expertise to our management team."
 
"All three of G1’s therapeutic candidates have the potential to become new standards of care for women with breast cancer, including in the adjuvant setting, and trilaciclib may improve patient outcomes across a range of tumor types," said Mr. Avagliano. "I’m excited about the opportunity to lead initiatives focused on making these therapies available globally to patients who need better treatment options."

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com